Developing novel chemical entities for the treatment of lysosomal storage disorders: An academic perspective

American Journal of Physiology - Renal Physiology

Volumn 309, Issue 12, 2015, Pages F996-F999

  Shayman, James A ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Eliglustat tartrate; Gaucher disease; Glucosylceramide; Glucosylceramide synthase; Lysosomal storage disease

Indexed keywords

2 DECANOYLAMINO 3 MORPHOLINO 1 PHENYL 1 PROPANOL; ELIGLUSTAT; GLOBOTRIAOSYLCERAMIDE; GLUCOSYLCERAMIDE; ENZYME INHIBITOR;

ARTICLE; CELL ACTIVATION; CELL PROLIFERATION; CELLULAR DISTRIBUTION; DRUG SYNTHESIS; GAUCHER DISEASE; LIPID METABOLISM; NONHUMAN; PERIPHERAL NEUROPATHY; PHENOTYPE; PRIORITY JOURNAL; TISSUE SPECIFICITY; ANIMAL; DRUG DEVELOPMENT; HUMAN; INDUSTRY; LYSOSOMAL STORAGE DISEASES; RESEARCH; TRENDS;

ANIMALS; DRUG DISCOVERY; ENZYME INHIBITORS; GAUCHER DISEASE; HUMANS; INDUSTRY; LYSOSOMAL STORAGE DISEASES; RESEARCH;

EID: 84959209473     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00393.2015     Document Type: Article

References (21)

1. Abe A, Gregory S, Lee L, Killen PD, Brady RO, Kulkarni A, Shayman JA. Reduction of globotriaosylceramide in Fabry disease mice by substrate deprivation. J Clin Invest 105: 1563-1571, 2000.
2. Barton NW, Brady RO, Dambrosia JM, Di Bisceglie AM, Doppelt SH, Hill SC, Mankin HJ, Murray GJ, Parker RI, Argoff CE, et al. Replacement therapy for inherited enzyme deficiency-macrophage-targeted glucocerebrosidase for Gaucher's disease. N Engl J Med 324: 1464-1470, 1991.
3. Cox TM. Eliglustat tartrate, an orally active glucocerebroside synthase inhibitor for the potential treatment of Gaucher disease and other lysosomal storage diseases. Curr Opin Invest Drugs 11: 1169-1181, 2010.
4. Cox TM, Drelichman G, Cravo R, Balwani M, Burrow TA, Martins AM, Lukina E, Rosenbloom B, Ross L, Angell J, Puga AC. Eliglustat compared with imiglucerase in patients with Gaucher's disease type 1 stabilised on enzyme replacement therapy: a phase 3, randomised, openlabel, non-inferiority trial. Lancet 385: 2355-2362, 2015.
5. Deegan PB, Cox TM. Imiglucerase in the treatment of Gaucher disease: a history and perspective. Drug Des Dev Ther 6: 81-106, 2012.
6. Futerman AH, van Meer G. The cell biology of lysosomal storage disorders. Nat Rev Mol Cell Biol 5: 554-565, 2004.
7. Hollak CE, van Weely S, van Oers MH, Aerts JM. Marked elevation of plasma chitotriosidase activity. A novel hallmark of Gaucher disease. J Clin Invest 93: 1288-1292, 1994.
8. Inokuchi J, Radin NS. Preparation of the active isomer of 1-phenyl-2-decanoylamino-3-morpholino-1-propanol, inhibitor of murine glucocerebroside synthetase. J Lipid Res 28: 565-571, 1987.
9. Kesselheim AS. An empirical review of major legislation affecting drug development: past experiences, effects, and unintended consequences. Milbank Q 89: 450-502, 2011.
10. Lee L, Abe A, Shayman JA. Improved inhibitors of glucosylceramide synthase. J Biol Chem 274: 14662-14669, 1999.
11. Lukina E, Watman N, Arreguin EA, Banikazemi M, Dragosky M, Iastrebner M, Rosenbaum H, Phillips M, Pastores GM, Rosenthal DI, Kaper M, Singh T, Puga AC, Bonate PL, Peterschmitt MJ. A phase 2 study of eliglustat tartrate (Genz-112638), an oral substrate reduction therapy for Gaucher disease type 1. Blood 116: 893-899, 2010.
12. McEachern KA, Fung J, Komarnitsky S, Siegel CS, Chuang WL, Hutto E, Shayman JA, Grabowski GA, Aerts JM, Cheng SH, Copeland DP, Marshall J. A specific and potent inhibitor of glucosylceramide synthase for substrate inhibition therapy of Gaucher disease. Mol Genet Metab 91: 259-267, 2007.
13. Mistry PK, Belmatoug N, vom Dahl S, Giugliani R. Understanding the natural history of Gaucher disease. Am J Hematol 90, Suppl 1: S6-S11, 2015.
14. Mistry PK, Lukina E, Ben Turkia H, Amato D, Baris H, Dasouki M, Ghosn M, Mehta A, Packman S, Pastores G, Petakov M, Assouline S, Balwani M, Danda S, Hadjiev E, Ortega A, Shankar S, Solano MH, Ross L, Angell J, Peterschmitt MJ. Effect of oral eliglustat on splenomegaly in patients with Gaucher disease type 1: the ENGAGE randomized clinical trial. JAMA 313: 695-706, 2015.
15. Morell P, Radin NS. Synthesis of cerebroside by brain from uridine diphosphate galactose and ceramide containing hydroxy fatty acid. Biochemistry 8: 506-512, 1969.
16. Poole RM. Eliglustat: first global approval. Drugs 74: 1829-1836, 2014.
17. Radin NS. Treatment of Gaucher disease with an enzyme inhibitor. Glycoconj J 13: 153-157, 1996.
18. Radin NS, Berent SL. Protein activator (coglucosidase) for the hydrolysis of beta-glucosides. Methods Enzymol 83: 596-603, 1982.
19. Radin NS, Brown JR, Lavin FB. The preparative isolation of cerebrosides. J Biol Chem 219: 977-983, 1956.
20. Shayman JA. Eliglustat tartrate: glucosylceramide synthase inhibitor treatment of type 1 Gaucher disease. Drugs Future 35: 613-620, 2010.
21. Shayman JA, Kelly R, Kollmeyer J, He Y, Abe A. Group XV phospholipase A2, a lysosomal phospholipase A2. Prog Lipid Res 50: 1-13, 2011.